NATICK, Mass., March 29, 2011 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced its clinical trial news and events schedule at the 60th Annual Scientific Session of the American College of Cardiology/i2 Summit, April 2-5, 2011 in New Orleans.
“Twelve-month results from the PLATINUM Workhorse clinical trial will provide important data on our next-generation PROMUS Element™ Everolimus-Eluting Platinum Chromium (PtCr) Stent as compared to our market-leading PROMUS® Stent,” said Keith D. Dawkins, M.D., Senior Vice President and Chief Medical Officer for Boston Scientific’s Cardiology, Rhythm and Vascular (CRV) Group. “Additional analysis from the PERSEUS trial will further demonstrate differences in the PtCr platform compared to prior-generation stents.”
Schedule of Events (All times are CST, with events to be held at the Ernest N. Morial Convention Center.)
Sunday, April 3
- Comparison of PERSEUS/ATLAS trial data. Dean Kereiakes, M.D., will present an analysis of case-matched data from 2,298 patients enrolled in the PERSEUS and TAXUS ATLAS clinical trials. The study will compare nine-month angiographic and 12-month clinical outcomes of the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System (TAXUS® Element™) to the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System. Both stents use the same drug and polymer but differ in metal alloy composition, stent design and strut thickness. Results will be presented from 10 to 11:15 a.m. during a poster session in Hall F. The Company plans to issue a press release announcing trial results at this time.
- Cost Effectiveness of ION Stent in Small Vessels. Mark Turco, M.D., will present an analysis of the cost effectiveness of the ION Stent (TAXUS Element) versus the bare-metal Express® Stent in patients with small vessels. Results will be presented from 10 to 11:15 a.m. during a poster session in Hall F.
- PROMUS Stent in Small Vessels. Jennifer Jones, M.D., will present 12-month results from the SPIRIT Small Vessel trial evaluating the safety and effectiveness of the 2.25 mm XIENCE V® (2.25 mm PROMUS®) Everolimus-Eluting Coronary Stent System in treating coronary artery lesions in small vessels. Results will be presented from 10 to 11:15 a.m. during a poster session in Hall F.
Monday, April 4
- PLATINUM Workhorse 12-month outcomes. Gregg Stone, M.D., the Global Principal Investigator of the PLATINUM clinical program, will present 12-month results from the PLATINUM Workhorse trial. The randomized, controlled trial enrolled 1,530 patients at 132 sites worldwide and compares the PROMUS Element Everolimus-Eluting Platinum Chromium Coronary Stent System to the PROMUS Everolimus-Eluting Coronary Stent System. Results will be presented in a late-breaking trial session from 11:39 to 11:51 a.m. in the Main Arena. The Company plans to issue a press release announcing trial results at this time.
- HORIZONS AMI Diabetic analysis. Bernhard Witzenbichler, M.D., will present results from an analysis of the HORIZONS AMI trial on the safety and effectiveness of the TAXUS Express® Stent in diabetic patients with acute myocardial infarction (AMI) undergoing primary angioplasty. HORIZONS AMI is the largest randomized trial to compare the use of drug-eluting stents to bare-metal stents for the treatment of heart attack patients. Results will be presented during an oral contributions session from 11:13 to 11:27 a.m. in Room 353.
- MADIT-CRT Changes in Outcomes after 12 months. Anne-Catherine Pouleur, M.D., will present results from the MADIT-CRT landmark clinical trial outlining the changes in left ventricle contractility and dyssynchrony after 12 months of resynchronization therapy. Results will be presented from 9:30 to 10:45 a.m. during a poster session in Hall F.
- MADIT-CRT Gender Relationship between QRS and Dyssynchrony. Dorit Knappe, M.D., will present results from the MADIT-CRT trial exploring gender relationships between QRS width and mechanical dyssynchrony. Results will be presented from 3:30 to 4:45 p.m. during a poster session in Hall F.
- Analyst Meeting. Boston Scientific will hold an analyst event providing an update on CRV Group initiatives involving coronary stent and structural heart technologies. The event is scheduled to begin at 6 p.m. and adjourn at approximately 7:15 p.m. following a brief question-and-answer session.
A live webcast of the event will be available to all interested parties via Boston Scientific’s website at www.bostonscientific.com. Webcast registration is available on the Investor Relations section of the website. Interested parties are encouraged to register at least 15 minutes prior to the scheduled start time to ensure a timely connection. A webcast replay will be archived and available on the Investor Relations section of the Company’s website approximately one hour following the completion of the event.
- Boston Scientific-Sponsored Symposium. The Company has provided an educational grant to theheart.org to support a CME-accredited symposium titled “Evolution in Stent Science: Understanding Tomorrow’s Technology Today,” chaired by Ted Feldman, M.D. The event will take place at The Westin New Orleans Canal Place from 7 to 9 p.m. It will feature presentations by leading interventional cardiologists examining the latest trends in coronary stent innovation, associated economics and their potential effect on future treatment options. A reception will be held prior to the symposium, beginning at 6:30 p.m.
Boston Scientific will present its latest drug-eluting stent, cardiac rhythm management, peripheral intervention and imaging technologies at booth #4121 in the Exhibit Hall.
TAXUS, Express, Liberte, PROMUS, Element and ION are trademarks of Boston Scientific Corporation or its affiliates. XIENCE V is a trademark of the Abbott Laboratories group of companies. The PROMUS Stent is a private-labeled XIENCE V Stent manufactured by Abbott and distributed by Boston Scientific. The SPIRIT clinical program is sponsored by Abbott.
In the U.S., the ION Stent, PROMUS Element Stent and 2.25 mm PROMUS (XIENCE V) Stent are investigational devices, limited by applicable law to investigational use only and not available for sale. The safety and effectiveness of the TAXUS Express Stent has not been established in diabetic patients or patients presenting with AMI.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.